Cellerix grants Axcan rights to Cx401 in North America
Madrid, 26th September 2007.- Cellerix, a biopharmaceutical company leader in the clinical development and production of medicines based on adult stem cells, has entered into an exclusive license and development agreement with Axcan Pharma Inc. ("Axcan") for the North American (United States, Canada and Mexico) rights to Cx401. Axcan is a leading multinational specialty pharmaceutical company focused on gastroenterology. It is listed on the NASDAQ Global Market and on the Toronto Stock...
more
West Announces First Quarter 2008 Results
LIONVILLE, Pa., May 1 2008-- West Pharmaceutical Services, Inc. (NYSE: WST) today announced results for the first quarter of 2008. Reported results included net after-tax benefits of $1.3 million, or $0.04 per diluted share, representing the combined effects of restructuring charges, a contract settlement gain and a discrete foreign tax benefit.
more
Sigma-Aldrich to Provide Full Functional Validation Data for Its MISSION(R) shRNA Collection
ST. LOUIS, May 7, 2008-- Sigma-Aldrich(TM) (Nasdaq: SIAL) and the second phase of The RNAi Consortium (TRC2) have commenced functional validation of the Consortium's collection of approximately 160,000 previously-cloned lentiviral-based shRNA vector constructs. Currently, more than 5,000 clones have been tested in the functional validation process. Validated clones covering more than 700 genes are available in Sigma-Aldrich's MISSION(R) shRNA collection, a number expected to grow by 75,000...
more